Systematic (IUPAC) name | |
---|---|
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine | |
Clinical data | |
Trade names | Ticlid |
AHFS/Drugs.com | monograph |
MedlinePlus | a695036 |
Pregnancy cat. | B1(AU) C(US) |
Legal status | ? |
Routes | Oral |
Pharmacokinetic data | |
Bioavailability | >80% |
Protein binding | 98% |
Metabolism | Hepatic |
Half-life | *12 hours (single dose) |
Excretion | Renal and fecal |
Identifiers | |
CAS number | 55142-85-3 |
ATC code | B01AC05 |
PubChem | CID 5472 |
DrugBank | APRD01257 |
ChemSpider | 5273 |
UNII | OM90ZUW7M1 |
KEGG | D08594 |
ChEBI | CHEBI:9588 |
ChEMBL | CHEMBL833 |
Chemical data | |
Formula | C14H14ClNS |
Mol. mass | 263.786 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. The usual dose is 250 mg twice daily by the oral route.
|